

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3681)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”) dated 22 December 2020 in relation to the proposed issue of Convertible Bonds (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, a circular containing further details in relation to the proposed issue of Convertible Bonds (the “**Circular**”) was expected to be despatched to the Shareholders on or before 14 January 2021. As additional time is required for the Company to prepare and finalise the information to be included in the Circular, the Company now expects to despatch the Circular to the Shareholders on or before 27 January 2021.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Director

Hong Kong, 14 January 2021

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the non-executive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Mr. Huiyuan MA and Mr. Jing QIANG, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Michael James Connolly HOGAN, Mr. Ping Cho Terence HON and Mr. Dylan Carlo TINKER.